Antibodies to fibrillarin, PM-Scl and RNA polymerase III detected by ELISA assays in patients with systemic sclerosis

Danilo Villalta, Gabriella Morozzi, Marilina Tampoia, Claudia Alpini, Ignazio Brusca, Valeria Salgarolo, Wolfgang Papisch, Nicola Bizzaro

Research output: Contribution to journalArticle

Abstract

Background: Anti-fibrillarin (AFA), anti-RNA polymerase (anti-RNAP), and anti-PM-Scl autoantibodies are useful markers for the diagnosis of systemic sclerosis (SSc) in patients who are anti-centromere- (ACA) or anti-topoisomerase I (anti-topo I)-negative, but, until recently, the only specific method for their identification was the radio-immunoprecipitation assay.The aim of this study was to evaluate the clinical accuracy of the new enzyme-linked immunosorbent assays (ELISA) developed by Phadia for their detection. Methods: Sera of 50 ACA and anti-topo I-negative SSc patients, and, as control group, sera of 122 patients (42 with SSc, ACA or anti-topo I-positive, 40 with systemic lupus erythematosus and 40 with rheumatoid arthritis) were studied. Result: Using the cutoff proposed by the manufacturer (10. AU/mL), sensitivity and specificity were: for AFA, 22% and 92.6%; for anti-RNAP, 16% and 97.5%; and for anti-PM-Scl, 8% and 98.8%, respectively. Using a cutoff corresponding to 98.8% specificity for all three antibodies, sensitivity was 10%, 14% and 8%, respectively. The combined use of these three antibody assays enabled identification of 32% of ACA- and anti-topo I-negative SSc patients. Conclusions: These new ELISA methods for AFA, anti-RNAP III and anti-PM-Scl detection have good diagnostic specificity, and may help identify a subset of SSc patients ACA and anti-topo I-negative.

Original languageEnglish
Pages (from-to)710-713
Number of pages4
JournalClinica Chimica Acta
Volume411
Issue number9-10
DOIs
Publication statusPublished - 2010

Fingerprint

RNA Polymerase III
Immunosorbents
Type I DNA Topoisomerase
Systemic Scleroderma
Assays
Enzyme-Linked Immunosorbent Assay
Antibodies
Enzymes
DNA-Directed RNA Polymerases
Centromere
Serum
Radio
Immunoprecipitation
Systemic Lupus Erythematosus
Autoantibodies
Rheumatoid Arthritis
fibrillarin
Sensitivity and Specificity
Control Groups

Keywords

  • Anti-fibrillarin (AFA) antibodies
  • Anti-PM-Scl antibodies
  • Anti-RNA polymerase (anti-RNAP) antibodies
  • Enzyme-linked immunosorbent assay (ELISA)
  • Sensitivity
  • Specificity
  • Systemic sclerosis (SSc)

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Antibodies to fibrillarin, PM-Scl and RNA polymerase III detected by ELISA assays in patients with systemic sclerosis. / Villalta, Danilo; Morozzi, Gabriella; Tampoia, Marilina; Alpini, Claudia; Brusca, Ignazio; Salgarolo, Valeria; Papisch, Wolfgang; Bizzaro, Nicola.

In: Clinica Chimica Acta, Vol. 411, No. 9-10, 2010, p. 710-713.

Research output: Contribution to journalArticle

Villalta, D, Morozzi, G, Tampoia, M, Alpini, C, Brusca, I, Salgarolo, V, Papisch, W & Bizzaro, N 2010, 'Antibodies to fibrillarin, PM-Scl and RNA polymerase III detected by ELISA assays in patients with systemic sclerosis', Clinica Chimica Acta, vol. 411, no. 9-10, pp. 710-713. https://doi.org/10.1016/j.cca.2010.01.037
Villalta, Danilo ; Morozzi, Gabriella ; Tampoia, Marilina ; Alpini, Claudia ; Brusca, Ignazio ; Salgarolo, Valeria ; Papisch, Wolfgang ; Bizzaro, Nicola. / Antibodies to fibrillarin, PM-Scl and RNA polymerase III detected by ELISA assays in patients with systemic sclerosis. In: Clinica Chimica Acta. 2010 ; Vol. 411, No. 9-10. pp. 710-713.
@article{bbde4186566d4d8d837d8858f4f4da7f,
title = "Antibodies to fibrillarin, PM-Scl and RNA polymerase III detected by ELISA assays in patients with systemic sclerosis",
abstract = "Background: Anti-fibrillarin (AFA), anti-RNA polymerase (anti-RNAP), and anti-PM-Scl autoantibodies are useful markers for the diagnosis of systemic sclerosis (SSc) in patients who are anti-centromere- (ACA) or anti-topoisomerase I (anti-topo I)-negative, but, until recently, the only specific method for their identification was the radio-immunoprecipitation assay.The aim of this study was to evaluate the clinical accuracy of the new enzyme-linked immunosorbent assays (ELISA) developed by Phadia for their detection. Methods: Sera of 50 ACA and anti-topo I-negative SSc patients, and, as control group, sera of 122 patients (42 with SSc, ACA or anti-topo I-positive, 40 with systemic lupus erythematosus and 40 with rheumatoid arthritis) were studied. Result: Using the cutoff proposed by the manufacturer (10. AU/mL), sensitivity and specificity were: for AFA, 22{\%} and 92.6{\%}; for anti-RNAP, 16{\%} and 97.5{\%}; and for anti-PM-Scl, 8{\%} and 98.8{\%}, respectively. Using a cutoff corresponding to 98.8{\%} specificity for all three antibodies, sensitivity was 10{\%}, 14{\%} and 8{\%}, respectively. The combined use of these three antibody assays enabled identification of 32{\%} of ACA- and anti-topo I-negative SSc patients. Conclusions: These new ELISA methods for AFA, anti-RNAP III and anti-PM-Scl detection have good diagnostic specificity, and may help identify a subset of SSc patients ACA and anti-topo I-negative.",
keywords = "Anti-fibrillarin (AFA) antibodies, Anti-PM-Scl antibodies, Anti-RNA polymerase (anti-RNAP) antibodies, Enzyme-linked immunosorbent assay (ELISA), Sensitivity, Specificity, Systemic sclerosis (SSc)",
author = "Danilo Villalta and Gabriella Morozzi and Marilina Tampoia and Claudia Alpini and Ignazio Brusca and Valeria Salgarolo and Wolfgang Papisch and Nicola Bizzaro",
year = "2010",
doi = "10.1016/j.cca.2010.01.037",
language = "English",
volume = "411",
pages = "710--713",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "9-10",

}

TY - JOUR

T1 - Antibodies to fibrillarin, PM-Scl and RNA polymerase III detected by ELISA assays in patients with systemic sclerosis

AU - Villalta, Danilo

AU - Morozzi, Gabriella

AU - Tampoia, Marilina

AU - Alpini, Claudia

AU - Brusca, Ignazio

AU - Salgarolo, Valeria

AU - Papisch, Wolfgang

AU - Bizzaro, Nicola

PY - 2010

Y1 - 2010

N2 - Background: Anti-fibrillarin (AFA), anti-RNA polymerase (anti-RNAP), and anti-PM-Scl autoantibodies are useful markers for the diagnosis of systemic sclerosis (SSc) in patients who are anti-centromere- (ACA) or anti-topoisomerase I (anti-topo I)-negative, but, until recently, the only specific method for their identification was the radio-immunoprecipitation assay.The aim of this study was to evaluate the clinical accuracy of the new enzyme-linked immunosorbent assays (ELISA) developed by Phadia for their detection. Methods: Sera of 50 ACA and anti-topo I-negative SSc patients, and, as control group, sera of 122 patients (42 with SSc, ACA or anti-topo I-positive, 40 with systemic lupus erythematosus and 40 with rheumatoid arthritis) were studied. Result: Using the cutoff proposed by the manufacturer (10. AU/mL), sensitivity and specificity were: for AFA, 22% and 92.6%; for anti-RNAP, 16% and 97.5%; and for anti-PM-Scl, 8% and 98.8%, respectively. Using a cutoff corresponding to 98.8% specificity for all three antibodies, sensitivity was 10%, 14% and 8%, respectively. The combined use of these three antibody assays enabled identification of 32% of ACA- and anti-topo I-negative SSc patients. Conclusions: These new ELISA methods for AFA, anti-RNAP III and anti-PM-Scl detection have good diagnostic specificity, and may help identify a subset of SSc patients ACA and anti-topo I-negative.

AB - Background: Anti-fibrillarin (AFA), anti-RNA polymerase (anti-RNAP), and anti-PM-Scl autoantibodies are useful markers for the diagnosis of systemic sclerosis (SSc) in patients who are anti-centromere- (ACA) or anti-topoisomerase I (anti-topo I)-negative, but, until recently, the only specific method for their identification was the radio-immunoprecipitation assay.The aim of this study was to evaluate the clinical accuracy of the new enzyme-linked immunosorbent assays (ELISA) developed by Phadia for their detection. Methods: Sera of 50 ACA and anti-topo I-negative SSc patients, and, as control group, sera of 122 patients (42 with SSc, ACA or anti-topo I-positive, 40 with systemic lupus erythematosus and 40 with rheumatoid arthritis) were studied. Result: Using the cutoff proposed by the manufacturer (10. AU/mL), sensitivity and specificity were: for AFA, 22% and 92.6%; for anti-RNAP, 16% and 97.5%; and for anti-PM-Scl, 8% and 98.8%, respectively. Using a cutoff corresponding to 98.8% specificity for all three antibodies, sensitivity was 10%, 14% and 8%, respectively. The combined use of these three antibody assays enabled identification of 32% of ACA- and anti-topo I-negative SSc patients. Conclusions: These new ELISA methods for AFA, anti-RNAP III and anti-PM-Scl detection have good diagnostic specificity, and may help identify a subset of SSc patients ACA and anti-topo I-negative.

KW - Anti-fibrillarin (AFA) antibodies

KW - Anti-PM-Scl antibodies

KW - Anti-RNA polymerase (anti-RNAP) antibodies

KW - Enzyme-linked immunosorbent assay (ELISA)

KW - Sensitivity

KW - Specificity

KW - Systemic sclerosis (SSc)

UR - http://www.scopus.com/inward/record.url?scp=77950459559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950459559&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2010.01.037

DO - 10.1016/j.cca.2010.01.037

M3 - Article

C2 - 20138166

AN - SCOPUS:77950459559

VL - 411

SP - 710

EP - 713

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 9-10

ER -